statistically significant, due Proportion with an death, or warfarin. Stroke survivors expected to have moderate impairment to a lack of power. atherosclerotic plaque in the haemorrhagic ARCH provides the impetus for (Rankin scale 2) at baseline. thoracic aorta = 14% stroke. further hypothesis formation and additional trials. N= 4,116 Outcome Difference in N if Health Economic QALY impact Economic impact on Total Economic Impact risk between implemented at service cost Impact on health per person QALYS if control and 65% per person or service costs if implemented treatment day implemented Primary Composite -33% -100 - $37,130 -$4m -$0.3m -$26m -$29m outcome Change in -$2m intervention costs -$4m -$26m -$32m Totals Columns may not sum due to rounding. Negative values are savings in the calculations. Health Health Service or service/outcome cost Explanation and costing assumptions Reference Outcome per person or day
statistically significant, due to a lack of power. death, or haemorrhagic stroke. warfarin. ARCH provides the impetus for further hypothesis formation and additional trials. Stroke survivors expected to have moderate impairment (Rankin scale 2) at baseline. Proportion with an atherosclerotic plaque in the thoracic aorta = 14% N= 4,116 Outcome Difference in risk between control and treatment N if implemented at 65% Health service cost per person or day Economic Impact on health service costs if implemented QALY impact per person Economic impact on QALYS if implemented Total Economic Impact Primary Composite outcome -33% -100 - $37,130 -$4m -$0.3m -$26m -$29m Change in intervention costs Totals -$2m -$4m -$26m -$32m Columns may not sum due to rounding. Negative values are savings in the calculations. Health Service or Outcome Health service/outcome cost per person or day Explanation and costing assumptions Reference
Supplementary-Appendix-B-Economic-evaluation-of-investigator-initiated-clinical-trials-conducted-by-networks.docx